Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, reported progress in interim results from its Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Details were anounced at the 7th International Investigative Dermatology meeting held last weekend in Orlando.    Four adult patients (n=7 wounds) aged…